BTIG raises Oruka Therapeutics price target on trial results By Investing.com

BTIG raised Oruka Therapeutics' price target to $151 from $78 and kept a Buy rating after 16-week EVERLAST-A data showed 63.5% complete skin clearance and a 64% PASI100 rate for ORKA-001. The firm boosted its probability of success to 90% and said the drug could support once-a-year maintenance dosing, with 28-week data due in H2 2026 and Phase 2b EVERLAST-B data in 2027. Oruka shares trade at $83.41, up 584% over the past year, and Wall Street’s consensus remains Strong Buy.

Analysis

ORKA is behaving less like a single-asset biotech and more like a platform re-rating on the possibility of defining a new dosing standard in IL-23. If management can credibly push maintenance toward annual dosing, the economic moat is not just efficacy but adherence: payers and physicians tend to reward therapies that lower visit frequency, reduce injection fatigue, and simplify refill logistics. That creates a second-order advantage against incumbents even if absolute efficacy converges over time, because real-world persistence can become the bigger driver of share than headline trial deltas.

The near-term winner is likely the entire psoriasis biologics ecosystem on valuation comparables, but the loser is the market’s willingness to underwrite long-duration cash burn at current implied expectations. The stock is now pricing a fairly clean clinical arc; that makes the next 6-18 months more binary, with any signal of immunogenicity, durability decay, or less-than-seamless scale-up likely to compress the multiple quickly. The market may also be underestimating that a best-in-class claim in psoriasis can spill into other inflammatory indications only if the PK/PD package supports it, so the upside is broader but the proof burden is also broader.

Contrarian risk: this is exactly the type of biotech move that can overshoot fundamentals when one clean dataset is extrapolated across a multi-year pipeline. The biggest gap between price and reality is probably not efficacy, but commercial execution and probability-weighted timing; even a superior drug can underperform if launch is delayed, labeling is narrower than expected, or payers force step-edits around entrenched standards. In that sense, the stock’s optionality is strong, but the forward return from here is likely much more sensitive to the next two data readouts than to today’s headline target raises.

Key Decisions for Investors

• Long ORKA on pullbacks only; use a 4-8 week window and target a re-test of the post-data high, but keep size modest because the current valuation already embeds a high-success case.
• Buy ORKA call spreads 6-12 months out instead of stock to capture upside from the next data catalyst while capping downside if durability or safety questions emerge.
• Pair trade: long ORKA / short a basket of slower-growing psoriasis biologic leaders on a 3-6 month horizon to express relative superiority in dosing convenience and share capture, not absolute biotech beta.
• If already long, trim into strength above consensus target levels and retain a residual position for 2026-2027 readouts; the risk/reward worsens materially once the market prices near-perfect execution.
• For event-driven accounts, set a hard stop on any sign that later-stage data dilute the annual-dosing narrative; that would be the main thesis breaker and could de-rate the stock sharply within days.